Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Mike Ouimette Sells 13,270 Shares of Stock

Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Mike Ouimette sold 13,270 shares of the firm’s stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $11.20, for a total transaction of $148,624.00. Following the completion of the sale, the general counsel now owns 80,774 shares of the company’s stock, valued at approximately $904,668.80. This trade represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Mike Ouimette also recently made the following trade(s):

• On Wednesday, January 22nd, Mike Ouimette sold 10,230 shares of Pliant Therapeutics stock. The shares were sold at an average price of $10.99, for a total value of $112,427.70.

Pliant Therapeutics Stock Performance

Shares of PLRX stock opened at $10.92 on Thursday. The business has a fifty day moving average of $13.24 and a 200 day moving average of $13.08. Pliant Therapeutics, Inc. has a 1 year low of $10.22 and a 1 year high of $18.92. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.26 and a current ratio of 10.26.

Pliant Therapeutics (NASDAQ:PLRX) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.99) by $0.04. Equities research analysts anticipate that Pliant Therapeutics, Inc. will post -3.65 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $38.00 target price on shares of Pliant Therapeutics in a research report on Friday, November 8th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $40.50.

Hedge Funds Weigh In On Pliant Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Atria Investments Inc purchased a new position in shares of Pliant Therapeutics during the third quarter worth $112,000. Deerfield Management Company L.P. Series C purchased a new position in shares of Pliant Therapeutics during the 2nd quarter valued at about $126,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Pliant Therapeutics by 65.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,694 shares of the company’s stock valued at $131,000 after buying an additional 4,607 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of Pliant Therapeutics in the third quarter worth about $145,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Pliant Therapeutics in the third quarter worth about $342,000. 97.30% of the stock is owned by hedge funds and other institutional investors.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.